Skip to main content

VistaGen Is Prepared For 2021 Fueled By Recent Analyst Upgrades And Large Institutional Buyers

VistaGen’s deal with Pherin Pharmaceuticals to develop PH-94B has positioned the Company to grab a healthy share of, social anxiety, and major depression markets.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.